This review describes the chronotherapeutic
strategies based on molecular clock system of chronopharmacokinetic,
chronopharmacodynamic and cancer chronopathological factors in the xenobiotic
detoxification, transporter, receptor and molecular target. Chronotherapeutic strategies focus on the monitoring of rhythm, overcoming rhythm disruption,
manipulation of rhythm, chrono-therapeutic drug monitoring, chrono-drug delivery system and chrono-drug discovery. The screening for small molecules targeting
the clock genes is now in progress to stabilize circadian phase and enhance
circadian amplitude, thereby consolidating and coordinating circadian
organization,.
The academic research along with a combination of chemical and biological
information is essential to promote the research and development of new
modality drug discovery such as clock genes.
Ramelteon,
a melatonin receptor agonist, has a sleep-promoting effect by modulating sleep-wake
rhythms. To examine the effect of ramelteon on cardiac function, authors simultaneously
recorded electrocardiograms, electromyograms, and electrocorticograms in the
frontal cortex and the olfactory bulb of unrestrained rats treated with
ramelteon. Authors demonstrated that during non-REM sleep, heartrate
variability was maintained by ramelteon treatment. Analysis of the
electromyograms confirmed that neither microarousal during non-REM sleep nor
the occupancy of phasic periods during REM sleep was altered by ramelteon. Thus,
authors propose a remedial effect of ramelteon on cardiac activity by keeping
the heartrate
variability.
Numerous studies have confirmed that the
sFlt1/PlGF ratio is a good predictor of the signs and symptoms of Pre-Eclampsia.
However, its usefulness is limited to diagnosis after 20 weeks of gestation. To
address this issue, in the present study the authors used plasma samples
collected at gestational weeks 14-24 weeks from subjects who were subsequently
diagnosed as Pre-Eclampsia. By employing SWATH-based proteomics for
comprehensive discovery and SRM-based target quantification using in silico
peptide selection criteria for validation, the authors were able to identify a
3-protein combination biomarker (AFAM, FINC and SHBG) that can predict
effectively during gestational weeks 14-24 whether pregnant women would
subsequently develop Pre-Eclampsia.
Cisplatin is an
effective anti-cancer drug. A serious major side effect of cisplatin is an
acute kidney injury. The authors demonstrated that panduratin A, a bioactive
flavonoid, ameliorates cisplatin-induced nephrotoxicity by inhibition of cell
apoptosis. The renoprotective effect of panduratin A is mediated by reducing
oxidative stress and inhibiting ERK1/2 and caspase 3 activations. The
protective effect of panduratin A did not impair the anti-cancer activity of
cisplatin in cancer cells. Panduratin A might be a good candidate agent to
alleviate cisplatin’s nephrotoxicity.
Influenza causes nosocomial outbreaks in healthcare
settings. Post-exposure prophylaxis (PEP) for healthcare workers is one of the
effective strategies for preventing outbreaks of influenza. However, PEP
adherence in healthcare workers is rarely analysed. This retrospective questionnaire-based study showed
that the adherence to PEP among healthcare workers was low, especially among
physicians, and that the primary factor for preventing PEP adherence was misguided
self-decision that continuation of PEP was unnecessary. This study emphasized
that medication education should be provided to ensure treatment compliance and
maximize the therapeutic benefits of PEP when PEP is administered.